Scientific Affairs

Saint-Maur-des-Fossés, France

Scientific Affairs

Saint-Maur-des-Fossés, France

Time filter

Source Type

News Article | May 11, 2017
Site: www.businesswire.com

LONDON & WILMINGTON, N.C.--(BUSINESS WIRE)--Chiltern, a leading global contract research organization, will host a complimentary Xtalks webinar, “Imaging Diagnostics and Theranostics: Meeting Clinical Development Challenges.” The live session will feature thought leaders from Chiltern speaking about the new tools that have evolved in the imaging diagnostic and theranostic space and the opportunities they provide to improve the diagnosis and treatment of cancers and other diseases. “Although challenges remain, this is an exciting time to be in clinical research,” said Sapna Hornyak, MS, MBA, executive vice president, medical device & diagnostics. “This presentation will introduce viewers to the diagnostic and theranostic agents currently under development and discuss the ways they are being implemented and utilized.” Among the key topics to be discussed are innovative tools for diagnostic imaging and treatment of cancers and other diseases, the regulatory expectations for these products, and the clinical development challenges they represent. The webinar will take place May 17 at 10 a.m. (EDT). Register at ChilternWebinar.com. To learn more about this topic or get in touch with Chiltern’s Medical Device & Diagnostics team, visit Chiltern.com or schedule a meeting at the SNMMI 2017 Annual Meeting, June 10–14, in Denver, Colorado. About Chiltern Chiltern, a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit Chiltern.com to learn more about how Chiltern is Designed Around You®.


"The data presented at the ESTRO 36 meeting continue to show that the benefits of the TomoTherapy® System's ring gantry platform and daily 3D  image guidance in the treatment of a range of clinical indications." said Fabienne Hirigoyenberry, VP Global Medical and Scientific Affairs of Accuray. "The Radixact™ System, the latest generation TomoTherapy platform, provides the same unrivaled delivery capabilities while giving clinicians the versatility to treat the broad spectrum of patients and disease types with the highest level of precision and increased speed and efficiency." Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com.http://www.accuray.com. Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.


News Article | May 9, 2017
Site: www.eurekalert.org

ORION is a new collaborative European project to explore ways in which research and funding organizations in life sciences and biomedicine can open up the way they fund, organize and do research. Open science is a core strategy of the European Commission that involves widening participation and collaboration as well as sharing research processes and outcomes to improve research and innovation. All European Union members recognise the benefits of open science, but the transition to "openness" is challenging. The ORION project will help research and funding organizations to understand existing challenges in Open Science and implement institutional, cultural, and behavioral changes in how they carry out and manage research. "New models of working require novel cooperative approaches that engage lots of different actors, such as researchers, funders, publishers, patient organisations, citizens, students, teachers, or companies," explains Michela Bertero, coordinator of the ORION project and responsible for International and Scientific Affairs at the Centre for Genomic Regulation in Barcelona, Spain. "It is often difficult to open up fundamental research in life sciences and biomedicine to different stakeholders, particularly citizens, so the ORION project will be both challenging and interesting," she adds. At the heart of the project will be open "co-creation" experiments that engage multiple stakeholders and explore different ways to make scientific research more participatory and inclusive. The experiments will tackle questions such as: how can research organisations receive input from a multitude of stakeholders? How can research funding be made more inclusive? How can public dialogue inform research policy and research content? How can citizens be involved in fundamental research projects? We will organize, for example, open dialogues with multiple actors on controversial research topics and launch innovative projects on fundamental research that entail participation of citizens and different experts. The results from the experiments will be developed into good practice and concrete actions that research and funding organisations can implement. ORION will also generate new training content for professionals working in funding agencies, to raise knowledge and awareness about Open Science and RRI, Responsible research and innovation. RRI is a concept helping organisations to incorporate the principles of ethics, gender, good governance, open access, public engagement, and science education in their policies, practices and processes. Focus will be on controversial research topics, e.g. animal research, genome editing, personalised medicine or stem cell research, and their medical applications. Partners are committed to sharing lessons learnt and case studies with other organisations as well as developing a tailored action plan on Open Science and RRI for their own organisation. The project will result in a wide range of material, training, good practices, reports and publications that will be disseminated freely and widely across Europe. ORION is a four-year project with a 3.2 million Euros budget funded under the European Commission's Horizon 2020 programme. Partners in the consortium (see list below) represent a mixture of expertise in fundamental research in life sciences and biomedicine, social sciences, funding, science communication, public engagement, and civil society. The project will be working closely with EU-LIFE, an alliance of top life science research institutes in 13 European countries.


"The data presented at the ESTRO 36 meeting continue to show that the benefits of the TomoTherapy® System's ring gantry platform and daily 3D  image guidance in the treatment of a range of clinical indications." said Fabienne Hirigoyenberry, VP Global Medical and Scientific Affairs of Accuray. "The Radixact™ System, the latest generation TomoTherapy platform, provides the same unrivaled delivery capabilities while giving clinicians the versatility to treat the broad spectrum of patients and disease types with the highest level of precision and increased speed and efficiency." Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com. Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-data-reinforce-benefits-of-tomotherapy-platform-for-mainstream-radiation-therapy-treatment-indications-300455781.html


News Article | May 10, 2017
Site: www.prnewswire.com

The American Academy of Orthopaedic Surgeons estimates about 53,000 people in the United States have shoulder replacement surgery each year. The benefits of replacing both sides of the joint with a total shoulder arthroplasty have been well established, however, glenoid loosening remains the Achilles Heel of the procedure. "According to the literature, 2-10% of patients treated with a standard total shoulder replacement will require a revision procedure within the first decade following surgery due to onlay glenoid component loosening. Inlay arthroplasty may provide a solution to lower the revision burden on patients and the healthcare system," said Matthias Schurhoff, VP of Clinical Operations and Scientific Affairs at Arthrosurface. The company's OVO™ Primary Stemless Shoulder System with inlay glenoid replacement was launched in the US in 2009 and has experienced excellent surgeon adoption. The inherent advantages are particularly well suited for younger and active patients requiring shoulder joint replacement surgery. Arthrosurface, Inc. is a global orthopedic medical technology business providing a broad portfolio of essential products and instrumentation used to treat upper and lower extremity conditions caused by trauma, injury and arthritic disease. The product offerings include devices, instruments and orthobiologics designed to preserve and restore joints so patients can regain and maintain an active lifestyle. The Company offers a variety of unique systems that provide less invasive technologies for surgeons in the treatment of a wide variety of joint pathologies. Founded in 2002, Arthrosurface markets and distributes its products in the US and around the world and has succeeded in helping patients return to activity for over 13 years. For more information, please go to our website at www.arthrosurface.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shoulder-basic-science-reconfirms-benefits-of-inlay-arthroplasty-300455516.html


"Innovations in theoretical and computational chemistry underpin our understanding of biological interactions, chemical dynamics and structure, as well as many beneficial chemical technologies. Michele Parrinello is a giant in the field, whose innovations are widely used in chemistry, biology, materials science, and engineering," stated Matthew Tirrell, Chair of the Dreyfus Foundation Scientific Affairs Committee and Founding Pritzker Director of the Institute for Molecular Engineering at the University of Chicago. The impact of Parrinello's work is such that he is one of the most cited scientists in the present day. He is renowned for co-devising the Car–Parrinello method for computer simulation of the movements of atoms and molecules. This work brought together, for the first time, the classical approach of molecular dynamics with a quantum theoretical approach for electron densities. This enabled the realistic exploration of a wide range of physical situations. Prior to this Parrinello had become distinguished for developing the Parrinello–Rahman method to study phase transitions in crystals. More recently, he has developed what is called metadynamics and subsequently announced an efficient variational sampling process. This has allowed the calculation of complicated phenomena such as protein folding, crystallization from a liquid, or the binding of drugs to protein receptors. Henry C. Walter, President of the Dreyfus Foundation, said, "Michele Parrinello's contributions to chemistry are immense. The Dreyfus Foundation is proud to honor him with the Dreyfus Prize, and as the first recipient from outside the United States." "I am overjoyed and humbled by the honor," said Parrinello. "I would like to dedicate this prize to my mentor Anees Rahman, the founder of modern atomistic molecular dynamics, a superb scientist, and a great human being. It was my good fortune to have met him as well as the very many talented colleagues and students with whom I had the pleasure to collaborate." Born in Messina, Italy, Parrinello received his Italian Laurea in physics from the University of Bologna in 1968. He has received many international honors including the Dirac Medal, the Rahman Prize, the Hewlett-Packard Europhysics Prize (all with Roberto Car), the Schroedinger Medal, the Enrico Fermi Prize, and the American Chemical Society Award in Theoretical Chemistry. He is a Fellow of the American Physical Society, Socio corrispondente of the Accademia Nazionale dei Lincei (Italy), and a Member of the Royal Society (UK), the European Academy of Sciences, the National Academy of Sciences, the American Academy of Arts and Sciences, and others. The Camille and Henry Dreyfus Foundation (www.dreyfus.org), based in New York, is a leading non-profit organization devoted to the advancement of the chemical sciences. It was established in 1946 by chemist, inventor, and businessman Camille Dreyfus, who directed that the Foundation's purpose be "to advance the science of chemistry, chemical engineering, and related sciences as a means of improving human relations and circumstances throughout the world." In broad terms, the Foundation programs advance young faculty of early accomplishment, develop leadership in environmental chemistry, and fund lectureships at primarily undergraduate institutions. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/michele-parrinello-wins-the-dreyfus-prize-for-advances-in-theoretical-and-computational-chemistry-300456587.html


"Wir freuen uns über diesen Vertrauensbeweis. Die Anerkennung unserer Arbeit durch die DTRA stärkt die Positionierung von MeMed als Weltmarktführer auf dem Gebiet der immunbasierten Diagnostik von Infektionskrankheiten", bemerkte Dr. Eran Eden, CEO bei MeMed.  "Diese gemeinsame Anstrengung und unsere wachsende Zusammenarbeit mit anderen internationalen Interessenvertretern aus Industrie und Regierung wird die weltweite Verfügbarkeit unserer Tests zur Bekämpfung antimikrobieller Resistenzen ermöglichen." Während der letzten acht Jahre haben die Unternehmensmitgründer Dr. med. Kfir Oved und Dr. Eran Eden mit führenden Forschern und Klinikern aus der ganzen Welt zusammengearbeitet, um die Veränderungen zu untersuchen, die im menschlichen Immunsystem stattfinden, wenn es Infektionen bekämpft, und um eine menschliche Immunsignatur zu entwickeln, die den Unterschied zwischen bakteriellen und Virusinfektionen genau erkennt. ImmunoXpert™, das neuartige Testverfahren der ersten Generation, ist bereits in Gebrauch und hat sich an Tausenden von Patienten bewährt*. Das Testverfahren der zweiten Generation umfasste die Entwicklung einer neuen patientennahen Diagnoseplattform, die einfach zu handhaben ist und nur 15 Minuten Zeit in Anspruch nimmt. "Diese Zusammenarbeit wird uns ermöglichen, die Fertigstellung unserer patientennahen Diagnoseplattform zu beschleunigen", sagte Dr. med. Kfir Oved, CTO bei MeMed. "Die neue Plattform ermöglicht nicht nur innerhalb von Minuten Messungen unserer bakteriellen Tests im Vergleich zu viralen Tests, sondern ebnet darüber hinaus den Weg zu einer Vielzahl von Mehrfach-Proteinmessungen in Form von Schnelltests mit der Präzision einer Labordiagnostik für einen umfassenden Anwendungsbereich." "Das Projekt wird außerdem unser Testmenü zum frühen Erkennen von Infektionen bewerten und erweitern, sogar bereits in einem präsymptomatischen Krankheitsstadium, in dem noch keine Symptome vorliegen. Dies stellt zurzeit eine enorme Einschränkung unserer Fähigkeit dar, Infektionen und Epidemien unter Kontrolle zu halten", stellte Dr. Tanya Gottlieb, VP Scientific Affairs bei MeMed, fest. Die Defense Threat Reduction Agency (DTRA) wurde im Jahr 1998 als eine dem Verteidigungsministerium der Vereinigten Staaten angeschlossene Behörde gegründet und befasst sich mit der Verminderung der Bedrohung durch Massenvernichtungswaffen. Die Hauptaufgabe der DTRA besteht darin, die Bedrohung der Vereinigten Staaten und der restlichen Welt durch globale Massenvernichtungswaffen sowie improvisierte Bedrohungen einzudämmen. Dies geschieht durch Integration, Synchronisierung und die Bereitstellung von Fachwissen, Technologien und Fähigkeiten. Weitere Informationen zur DTRA erhalten Sie unter http://www.dtra.mil. MeMed engagiert sich für die Verbesserung der Lebensqualität von Patienten durch Forschung, Entwicklung und Vermarktung von bahnbrechenden Testverfahren, die den Immunstatus des Körpers überwachen. Die Tests von MeMed entschlüsseln die individuellen Reaktionen des Immunsystems auf unterschiedliche Gesundheits- und Erkrankungsstadien. Das Unternehmen konzentriert sich auf die Bereitstellung schneller, genauer und verfolgbarer Diagnostiklösungen für akute Infektionserkrankungen sowie Entzündungskrankheiten in Krankenhäusern und Gemeinden. ImmunoXpert™, das Testverfahren der ersten Generation des Unternehmens, hat die Fähigkeit bewiesen, genau zu erkennen, ob ein Patient an einer bakteriellen oder einer Viruserkrankung leidet. Dadurch werden Ärzte in die Lage versetzt, fundiertere Entscheidungen darüber zu treffen, ob eine Behandlung mit Antibiotika angezeigt ist. ImmunoXpert wurde für die klinische Verwendung in der Europäischen Union, der Schweiz und in Israel freigegeben. Zurzeit wird es in diesen Gebieten zu Proben verwendet. Eine weitere kommerzielle Verbreitung ist im Gang. Das Testverfahren der zweiten Generation von MeMed für schnelle Tests vor Ort (innerhalb von Minuten) befindet sich in der Entwicklung. Weitere Informationen erhalten Sie unter http://www.me-med.com.


"Wir freuen uns über diesen Vertrauensbeweis. Die Anerkennung unserer Arbeit durch die DTRA stärkt die Positionierung von MeMed als Weltmarktführer auf dem Gebiet der immunbasierten Diagnostik von Infektionskrankheiten", bemerkte Dr. Eran Eden, CEO bei MeMed.  "Diese gemeinsame Anstrengung und unsere wachsende Zusammenarbeit mit anderen internationalen Interessenvertretern aus Industrie und Regierung wird die weltweite Verfügbarkeit unserer Tests zur Bekämpfung antimikrobieller Resistenzen ermöglichen." Während der letzten acht Jahre haben die Unternehmensmitgründer Dr. med. Kfir Oved und Dr. Eran Eden mit führenden Forschern und Klinikern aus der ganzen Welt zusammengearbeitet, um die Veränderungen zu untersuchen, die im menschlichen Immunsystem stattfinden, wenn es Infektionen bekämpft, und um eine menschliche Immunsignatur zu entwickeln, die den Unterschied zwischen bakteriellen und Virusinfektionen genau erkennt. ImmunoXpert™, das neuartige Testverfahren der ersten Generation, ist bereits in Gebrauch und hat sich an Tausenden von Patienten bewährt*. Das Testverfahren der zweiten Generation umfasste die Entwicklung einer neuen patientennahen Diagnoseplattform, die einfach zu handhaben ist und nur 15 Minuten Zeit in Anspruch nimmt. "Diese Zusammenarbeit wird uns ermöglichen, die Fertigstellung unserer patientennahen Diagnoseplattform zu beschleunigen", sagte Dr. med. Kfir Oved, CTO bei MeMed. "Die neue Plattform ermöglicht nicht nur innerhalb von Minuten Messungen unserer bakteriellen Tests im Vergleich zu viralen Tests, sondern ebnet darüber hinaus den Weg zu einer Vielzahl von Mehrfach-Proteinmessungen in Form von Schnelltests mit der Präzision einer Labordiagnostik für einen umfassenden Anwendungsbereich." "Das Projekt wird außerdem unser Testmenü zum frühen Erkennen von Infektionen bewerten und erweitern, sogar bereits in einem präsymptomatischen Krankheitsstadium, in dem noch keine Symptome vorliegen. Dies stellt zurzeit eine enorme Einschränkung unserer Fähigkeit dar, Infektionen und Epidemien unter Kontrolle zu halten", stellte Dr. Tanya Gottlieb, VP Scientific Affairs bei MeMed, fest. Die Defense Threat Reduction Agency (DTRA) wurde im Jahr 1998 als eine dem Verteidigungsministerium der Vereinigten Staaten angeschlossene Behörde gegründet und befasst sich mit der Verminderung der Bedrohung durch Massenvernichtungswaffen. Die Hauptaufgabe der DTRA besteht darin, die Bedrohung der Vereinigten Staaten und der restlichen Welt durch globale Massenvernichtungswaffen sowie improvisierte Bedrohungen einzudämmen. Dies geschieht durch Integration, Synchronisierung und die Bereitstellung von Fachwissen, Technologien und Fähigkeiten. Weitere Informationen zur DTRA erhalten Sie unter http://www.dtra.mil. MeMed engagiert sich für die Verbesserung der Lebensqualität von Patienten durch Forschung, Entwicklung und Vermarktung von bahnbrechenden Testverfahren, die den Immunstatus des Körpers überwachen. Die Tests von MeMed entschlüsseln die individuellen Reaktionen des Immunsystems auf unterschiedliche Gesundheits- und Erkrankungsstadien. Das Unternehmen konzentriert sich auf die Bereitstellung schneller, genauer und verfolgbarer Diagnostiklösungen für akute Infektionserkrankungen sowie Entzündungskrankheiten in Krankenhäusern und Gemeinden. ImmunoXpert™, das Testverfahren der ersten Generation des Unternehmens, hat die Fähigkeit bewiesen, genau zu erkennen, ob ein Patient an einer bakteriellen oder einer Viruserkrankung leidet. Dadurch werden Ärzte in die Lage versetzt, fundiertere Entscheidungen darüber zu treffen, ob eine Behandlung mit Antibiotika angezeigt ist. ImmunoXpert wurde für die klinische Verwendung in der Europäischen Union, der Schweiz und in Israel freigegeben. Zurzeit wird es in diesen Gebieten zu Proben verwendet. Eine weitere kommerzielle Verbreitung ist im Gang. Das Testverfahren der zweiten Generation von MeMed für schnelle Tests vor Ort (innerhalb von Minuten) befindet sich in der Entwicklung. Weitere Informationen erhalten Sie unter http://www.me-med.com.


TUCSON, Ariz., Feb. 27, 2017 /PRNewswire/ -- More than 500 pathologists, oncologists, scientific researchers and healthcare leaders will converge in Tucson for the 13th annual Tucson Symposium, February 28 to March 1. The two-day conference, which is sponsored by Ventana Medical Systems, Inc., a member of the Roche Group, draws top scientific collaborators from around the globe to hear from leading experts about the latest hypotheses, breakthroughs and innovations in cancer research and treatments. Topics will focus on developments in immunotherapy, genomics, technology, tumor heterogeneity and cancer evolution and personalized healthcare. Tucson Symposium was conceived in 2005 by Ventana Medical Systems, Inc. Founder and Senior Vice President of Scientific Affairs Dr. Thomas Grogan to provide a forum for thought leaders to share scientific advancements in cancer research and medical practice. "We are extremely pleased to announce that our distinguished opening keynote speaker this year is Dr. Antoni Ribas, a leading oncologist who will speak to advances in revolutionary new immune blockade therapy," Grogan said. Ribas, who is a Professor of Medicine, Professor of Surgery and Professor of Molecular and Medical Pharmacology at the University of California at Los Angeles (UCLA), will deliver information on the unprecedented response to this new therapy in patients with multiple metastatic cancers as well as combination approaches to improving treatment options. Charles Swanton, PhD, of London's Francis Crick Institute – a leading expert on heterogeneity and cancer's drug resistant and incurable nature – will return to the Symposium for a third year to deliver the Day 2 keynote address on our expanding knowledge of tumor genetic heterogeneity. Other sessions stretch beyond the traditional bounds of pathology to include discussions on genomics and innovative technologies that are transforming the field, including novel, emerging multiplexing technologies. "Having hosted the Tucson Symposium for 13 years, we've reached a pinnacle in terms of the experts delivering content on a broad range of cancer-related topics," said Dr. Eric Walk, a pathologist who is Senior Vice President, Medical and Scientific Affairs, and Chief Medical Officer at Ventana Medical Systems, Inc. "They are imparting the most current, critical knowledge that will enrich and advance the field of medicine and scientific research." For more information on Tucson Symposium, held at the Hilton Tucson El Conquistador, please visit www.ventana.com/tucson-symposium/. About Ventana Medical Systems, Inc.   Ventana Medical Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms and digital pathology solutions optimize laboratory efficiencies to help reduce errors, support diagnosis and enable informed treatment decisions by anatomic pathology professionals. Together with Roche, Ventana is driving Personalized Healthcare through accelerated drug discovery and the development of companion diagnostics to identify the patients most likely to respond favorably to specific therapies. Visit www.ventana.com. All trademarks used or mentioned in this release are protected by law.


GUANGZHOU, China--(BUSINESS WIRE)--Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, offers the innovative nutritional supplement Ambrotose® which is clinically proven to provide cognitive support for young adult functions essential to reach their potential in the classroom. This is even more critical now as success in the upcoming Zhongkao and Gao Kao are essential for future academic advancement. According to human clinical trials published in peer reviewed journals, Ambrotose powders can positively impact brainwaves associated with attention in young adults and improve memory and alertness in middle-aged adults. The cognitive factors of focus, attention and memory are crucial for young adult students aiming for high academic achievement. “Clinical studies conducted by independent scientists who are experts in their fields have found that Ambrotose powder gives a helpful boost in memory, focus and attention as well as providing perceived beneficial changes in well-being,” said Dr. Rolando Maddela, MD, MPH, CCRP, Mannatech’s Director of Clinical Research and Scientific Affairs. “For young adults who are students, Ambrotose products can be a positive addition to a comprehensive approach to academic achievement. Ambrotose may also play an important role in the overall health and wellness of students, a factor that also contributes to academic success.” Dr. Maddela suggests that as little as four grams per day of Advanced Ambrotose® powder or capsules may help support some of the factors that contribute to success in the classroom. Mannatech is the pioneer in developing Glyconutritional technology, which includes Ambrotose powders. Ambrotose encourages cellular communication and is shown to support cognitive functions – including memory, focus and attention, as well as supporting the body’s immune and digestive systems to encourage overall health. Some of Mannatech’s Glyconutritional products are supported by industry-standard clinical studies, including 17 human clinical trials that have been published, 12 of which were double-blind, placebo-controlled studies — the gold standard for product validation. For more on Mannatech’s rigorous scientific research, please visit MannatechScience.org. Advanced Ambrotose is clinically tested to improve cognitive function and support the body’s immune system. For more information about Mannatech and its products, please visit www.MeiTaiChina.com.†^ Mannatech, Incorporated, offers a profound wellness experience that makes a difference in the lives of people across the world. Through its innovative Glyconutrition products, Mannatech changes lives, providing an unprecedented level of natural wellness, freedom and purpose. With more than 20 years of experience and operations in 26 markets, Mannatech is committed to transforming lives. For more information, visit MeiTaiChina.com. Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release. †Customers who invite other customers to the Mannatech China cross-border e-commerce site gain rewards for future product purchases or cash redemption. The e-commerce business model is not multi-level marketing or direct selling. ^Mannatech’s cross-border e-commerce model in China is a different opportunity from Mannatech’s MLM business in other markets. Our cross-border e-commerce model in China is not an MLM or direct selling business.

Loading Scientific Affairs collaborators
Loading Scientific Affairs collaborators